EVIO, Inc. entered into a letter of intent to acquire Leading Edge Pharms, Inc.
July 11, 2021
Share
EVIO, Inc. (OTCPK:EVIO) entered into a letter of intent to acquire Leading Edge Pharms, Inc("LEP") on July 12, 2021. EVIO will authorize issuance of additional shares to settle the transaction. EVIO will add at least two board members and executive positions from LEP. The transaction is subject to due diligence, pending regulatory review, EVIO shareholder approval and other customary closing conditions.
EVIO, Inc. is a diversified holding company. The Company provides analytical testing services to the agricultural and pharmaceutical industries, primarily for cannabis, hemp, and related products. The Company offers residential and commercial construction services. The Company also offers research and development and consulting services for participants in the cannabis and hemp industries. The Company tests products to verify the regulatory requirements for sale. Its subsidiaries include Smith Scientific Industries, LLC; Greenhaus Analytical Labs, LLC; Viridis Analytics, LLC; EVIO Labs OR, Inc.; C3 Labs, LLC; EVIO Labs Humboldt, LLC and Keystone Labs, Inc.
EVIO, INC. 
